# A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients

> **NCT00349427** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 256 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Rosiglitazone 4 mg

## Key facts

- **NCT ID:** NCT00349427
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2012-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00349427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00349427, "A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients". Retrieved via AI Analytics 2026-08-25 from https://api.ai-analytics.org/clinical/NCT00349427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*